Cargando…

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

BACKGROUND: Mechanisms by which Smac mimetics (SMs) interact with proteasome inhibitors (e.g., bortezomib) are largely unknown, particularly in multiple myeloma (MM), a disease in which bortezomib represents a mainstay of therapy. METHODS: Interactions between the clinically relevant IAP (inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Liang, Zhang, Yu, Leng, Yun, Dai, Yun, Kmieciak, Maciej, Kramer, Lora, Sharma, Kanika, Wang, Yan, Craun, William, Grant, Steven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407248/ https://www.ncbi.nlm.nih.gov/pubmed/30845975 http://dx.doi.org/10.1186/s13045-019-0713-x

Ejemplares similares

Examining the In Vitro Efficacy of the IAP Antagonist Birinapant as a Single Agent or in Combination With Dacarbazine to Induce Melanoma Cell Death
por: Vetma, Vesna, et al.
Publicado: (2017)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro
por: Sun, Hao, et al.
Publicado: (2021)

Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms
por: Nguyen, Tri, et al.
Publicado: (2018)

RETRACTED ARTICLE: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2017)

Retraction Note: Birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2021)

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells
por: Leng, Yun, et al.
Publicado: (2022)

Editorial Expression of Concern: birinapant sensitizes platinum-resistant carcinomas with high levels of cIAP to carboplatin therapy
por: La, V., et al.
Publicado: (2018)

IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
por: Perimenis, Philippos, et al.
Publicado: (2016)

Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2018)

SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway
por: Ding, Jun, et al.
Publicado: (2020)

Combinatorial Treatment of Birinapant and Zosuquidar Enhances Effective Control of HBV Replication In Vivo
por: Morrish, Emma, et al.
Publicado: (2020)

Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells
por: Li, Lin, et al.
Publicado: (2023)

Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant
por: Zakaria, Z, et al.
Publicado: (2016)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

Proteomic Analysis of Combined Gemcitabine and Birinapant in Pancreatic Cancer Cells
por: Zhu, Xu, et al.
Publicado: (2018)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

STK405759 as a combination therapy with bortezomib or dexamethasone, in in vitro and in vivo multiple myeloma models
por: Rozic, Gabriela, et al.
Publicado: (2018)

Clinical outcomes of bortezomib-based therapy in myeloma
por: Djebbari, Faouzi, et al.
Publicado: (2018)

Pharmacodynamic modeling of synergistic birinapant/paclitaxel interactions in pancreatic cancer cells
por: Niu, Jin, et al.
Publicado: (2020)

CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance
por: Tang, Hailong, et al.
Publicado: (2020)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist
por: Liu, Xin, et al.
Publicado: (2022)

The expanding role of IAP antagonists for the treatment of head and neck cancer
por: Kansal, Vikash, et al.
Publicado: (2023)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

Molecular subtype-specific responses of colon cancer cells to the SMAC mimetic Birinapant
por: Fichtner, Michael, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo
por: Weiss, C, et al.
Publicado: (2012)

JaponiconeA induces apoptosis of bortezomib-sensitive and -resistant myeloma cells in vitro and in vivo by targeting IKKβ
por: Zhang, Zilu, et al.
Publicado: (2022)

Drosophila IAP antagonists form multimeric complexes to promote cell death
por: Sandu, Cristinel, et al.
Publicado: (2010)

IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
por: Shekhar, Tanmay M., et al.
Publicado: (2016)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice
por: Wang, Hua, et al.
Publicado: (2018)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014)

Activity of Birinapant, a SMAC Mimetic Compound, Alone or in Combination in NSCLCs With Different Mutations
por: Colombo, Marika, et al.
Publicado: (2020)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy
por: Yun, Charles, et al.
Publicado: (2015)

IAP-IAP Complexes Required for Apoptosis Resistance of C. trachomatis–Infected Cells
por: Rajalingam, Krishnaraj, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_v4t2fj9566eq0jrnn8v6okumf1